Journal of the American College of Cardiology (JACC)Rilonacept’s Role in Treating Recurrent Pericarditis

Rilonacept represents a significant advancement as the first FDA-approved IL-1 antagonist specifically for recurrent pericarditis, offering targeted therapy for patients with idiopathic recurrent pericarditis and elevated CRP who cannot successfully wean from glucocorticoids.

⚕️ Key Clinical Considerations ⚕️

• Mechanism & Timeline: IL-1α/β antagonist reaching steady state in 6 weeks, with median pain improvement at 5 days and CRP normalization at 7 days.
• Evidence Base: Phase III RHAPSODY trial demonstrated 96% risk reduction (HR 0.04) versus placebo with superior symptom control (81% vs 25% symptom-free days).
• Patient Selection: Reserved for idiopathic recurrent pericarditis with elevated CRP after failure of standard therapy (aspirin, NSAIDs, colchicine, glucocorticoids).
• Safety Profile: Common adverse effects include injection-site reactions, upper respiratory infections, and hyperlipidemia requiring lipid monitoring.
• Immunosuppression Risk: Contraindicated with live vaccines; patients must report infections promptly due to immunosuppressive effects.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Counsel on $20,000 monthly cost, specialty pharmacy dispensing, weekly subcutaneous injections, and infection precautions with prompt reporting requirements.
• Practice Integration: Initial injection requires supervised administration for technique training; coordinate specialty pharmacy services and establish monitoring protocols for lipids and symptom assessment.
• Risk Management: Screen for active infections, complete required immunizations pre-treatment, avoid live vaccines, and monitor for teratogenic risks in pregnancy (use only if benefits justify fetal risk).
• Action Items: Establish lipid monitoring schedule, create patient education materials on injection technique and infection reporting, coordinate specialty pharmacy relationships for drug access.

More on Targeted Therapies